Idenix Pharmaceuticals PT Lowered to $3.00 (IDIX)
JMP Securities reduced their price target on shares of Idenix Pharmaceuticals (NASDAQ:IDIX) from $5.00 to $3.00 in a research note issued on Thursday, Analyst Ratings Net reports. JMP Securities’ target price points to a potential downside of 58.33% from the stock’s previous close.
Several other analysts have also recently commented on the stock. Analysts at Barclays reiterated an “equal weight” rating on shares of Idenix Pharmaceuticals in a research note to investors on Friday, January 10th. They now have a $5.00 price target on the stock, up previously from $4.00. Analysts at UBS AG upgraded shares of Idenix Pharmaceuticals from a “neutral” rating to a “buy” rating in a research note to investors on Monday, January 6th. They now have a $11.00 price target on the stock, up previously from $4.00. Three research analysts have rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating to the company’s stock. Idenix Pharmaceuticals has an average rating of “Hold” and a consensus price target of $5.33.
Shares of Idenix Pharmaceuticals (NASDAQ:IDIX) traded up 5.28% during mid-day trading on Thursday, hitting $7.58. 1,301,312 shares of the company’s stock traded hands. Idenix Pharmaceuticals has a 52-week low of $2.93 and a 52-week high of $9.32. The stock has a 50-day moving average of $6.40 and a 200-day moving average of $4.9. The company’s market cap is $1.016 billion.
Idenix Pharmaceuticals, Inc (NASDAQ:IDIX) is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.